While research into the exact mechanism that causes migraine is ongoing, CGRP is known to play a role in migraine pain2
CGRP acts at multiple sites along the trigeminovascular pathway, causing vasodilation, inflammation, and pain3
UBRELVY IS THE FIRST ACUTE TREATMENT FOR MIGRAINE THAT DIRECTLY BLOCKS CGRP5-7
CGRP plays a key role in migraine attacks, binding to CGRP receptors to cause pain, inflammation, and vasodilation1,2,8,9
Watch the UBRELVY mechanism of action
UBRELVY works differently than older acute migraine treatments—see how each works against migraine2,5,8
MIGRAINE PATHOPHYSIOLOGY
CGRP is released, causing meningeal vessel expansion and pain signaling1,2,9
UBRELVY
Targets the CGRP receptor itself, blocking CGRP from attaching5
TRIPTANS - 5HT1B/1D agonists that constrict blood vessels and prevent release of neuropeptides; those already released continue to circulate1-3,9
BARBITURATES - This class of drug acts by potentiating GABA-induced increases in chloride conductance. They enhance GABA binding to GABA A receptors10
NSAIDs - The main effect of nonsteroidal anti-inflammatory drugs is the blockade of cyclooxygenase (COX) receptors11
UBRELVY PHARMACOKINETIC PROFILE5
IL-UBR-220001 | September 2022